A.Shtaiwi
☆    

Jordan,
2020-07-17 12:51
(18 d 00:31 ago)

Posting: # 21732
Views: 391
 

 Design of Bi-layer products [Design Issues]

Dear All,

Hope you are well,

I want to ask if anyone has experience or knowledge about reference product with following formulation:
2 active ingredients, one found in the immediate release layer and the other in the modified release layer. The Test product has the same composition. If the product is intended to be submitted to Europe, is it required to analyse both active ingredients in all required studies for modified release products (single dose studies under fast and fed conditions and multiple dose study) or should we analyse active ingredient which found in the immediate release layer only in the single dose study (either fasting or fed as per the information stated in the spc of the product) and analyse other active ingredient in all studies.

I have checked the EMEA guideline for modified release products but I just found information about biphasic release product where the same active ingredient is released in immediate and sustained release form.

Thanks
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2020-07-17 14:30
(17 d 22:52 ago)

@ A.Shtaiwi
Posting: # 21733
Views: 357
 

 EMA: FDC products (lenghty post)

Hi A.Shtaiwi,

the EMEA (European Agency for the Evaluation of Medicinal Products) was renamed to EMA (European Medicines Agency) back in 2005. ;-)

Since you have two APIs, you have to assess both in all studies. See the EMA’s Guideline on clinical development of fixed combination medicinal products, Section 4.5:

[…] bioequivalence with the reference fixed combination medicinal product […] should be demonstrated for all active substances in the fixed combination medicinal product according to the relevant guidelines.


[image]One caveat: Some European agencies are increasingly concerned about ‘drifting’ of bioavailability (as mentioned in the GL) and may ask additionally for BE of the new combo versus single components or a justification why such a potential drift is clinically not relevant.
See Marina Feřtek’s presentation (BioBridges, Prague 2017). In your case that might not be possible if either the 1st API (IR component) or the 2nd API (MR component) are not – or no more – marketed as mono products.
Recently I supported an adjusted indirect comparisona,b for Czechia’s SÚKL; outcome pending.


  1. Adjusted indirect comparison because an adjustment is performed for different sample sizes and (optionally) within-subject variances which might differ between studies.
    Most papers1–11 on the topic were co-authored by regulators. The CI will always be wider than in a hypothetical head-to-head study because variances are additive. Furthermore, studies were not powered for such a comparison. Hence, a wider acceptance range of 70.00–142.86% was proposed.5
  2. Example
    1. Information
      1. PAR of the originator: Combo (TAB) vs. single components (RA, RB).
        Sample size, PE, and 90% CI of A(TAB) vs. RA and B(TAB) vs. RB.
      2. BE study: Generic combo (TAB) vs. originator’s combo (RAB).
        ANOVAs: A(TAB) vs. A(RAB) and B(TAB) vs. B(RAB).
    2. Indirect comparison
      1. Assume that TAB of the originator’s study = RAB of the BE study. Cross fingers that the reference does not show large batch-to-batch variability.
      2. Calculate PE and 90% CI of the generic combo vs. the components.

      • Simple example assuming equal sample sizes (point estimates only, the CI is tricky):
        Originator’s study (a.1.)
          Component A: PE =   95%
          Component B: PE = 110%
        Generic combo (a.2.)
          Component A: PE =  90%
          Component B: PE = 105%
        Indirect comparison
          Component A: PE = (  90 ×   95) / 100 =   85.5%
          Component B: PE = (105 × 110) / 100 = 115.5%

  1. Gwaza L, Gordon J, Welink J, Potthast H, Hansson H, Stahl M, García-Arieta A. Statistical approaches to indirectly compare bioequivalence between generics: a comparison of methodologies employing arte­me­ther / lume­fan­trine 20 / 120 mg tablets as prequalified by WHO. Eur J Clin Pharmacol. 2012; 68(12): 1611–8. doi:10.1007/s00228-012-1396-1.
  2. Herranz M, Morales-Alcelay S, Corredera-Hernández MA, de la Torre-Alvarado JM, Blázquez-Pérez A, Suá­rez-Gea ML, Álvarez C, García-Arieta A. Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison. Eur J Clin Pharmacol. 2013; 69(5): 1157–62. doi:10.1007/s00228-012-1456-6.
  3. Gwaza L, Gordon J, Welink J, Potthast H, Leufkens H, Stahl M, García-Arieta A. Adjusted Indirect Treatment Comparison of the Bioavailability of WHO‐Prequalified First‐Line Generic Antituberculosis Medicines. Clin Pharmacol Ther. 2014; 96(5): 580–8. doi:10.1038/clpt.2014.144.
  4. Yu Y, Teerenstra S, Neef C, Burger D, Maliepaard M. Investigation into the interchangeability of ge­neric formulations using immunosuppressants and a broad selection of medicines. Eur J Clin Pharmacol. 2015; 71(8): 979–80. doi:10.1007/s00228-015-1878-z. [image] Open access.
  5. Gwaza L, Gordon J, Potthast H, Welink J, Leufkens H, Stahl M, García-Arieta A. Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons. Eur J Clin Pharmacol. 2015; 71(9): 1083–9. doi:10.1007/s00228-015-1889-9.
  6. Gwaza L. Adjusted Indirect Treatment Comparisons of Bioequivalence Studies. PhD Thesis: Utrecht. 2016. [image] Open access.
  7. García Arieta A, Potthast H, Leufkens H, Welink J, Gordon J, Gwaza L, Maliepaard M, Stahl M. Assessment of the interchangeability between generics. GaBI J. 2016; 5(2): 55–9. doi:10.5639/gabij.2016.0502.015. [image] Open access.
  8. Gwaza L, Gordon J, Leufkens H, Stahl M, García-Arieta A. Global Harmonization of Comparator Products for Bioequivalence Studies. AAPS J. 2017; 19(3): 603–6. doi:10.1208/s12248-017-0068-6.
  9. Zheng J, Chow S-C, Yuan M. On assessing bioequivalence and interchangeability between generics based on indirect comparisons. Stat Med. 2017; 36(19): 2978–93. doi:10.1002/sim.7326.
  10. Wang YL, Hsu LF. Evaluating the Feasibility of Use of a Foreign Reference Product for Generic Drug Applications: A Retrospective Pilot Study. Eur J Drug Metab Pharmacokinet. 2017; 42(6): 935–42. doi:10.1007/s13318-017-0409-y.
  11. Pejčić Z, Vučićević K, García-Arieta A, Miljković B. Adjusted indirect comparisons to assess bioequivalence between generic clopidogrel products in Serbia. Br J Clin Pharmacol. 2019; 85: 2059–65. doi:10.1111/bcp.13997.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
A.Shtaiwi
☆    

Jordan,
2020-07-19 15:13
(15 d 22:09 ago)

@ Helmut
Posting: # 21750
Views: 200
 

 EMA: FDC products (lenghty post)

Thanks Helmut for these information
Activity
 Admin contact
20,964 posts in 4,373 threads, 1,460 registered users;
online 7 (0 registered, 7 guests [including 4 identified bots]).
Forum time: Tuesday 13:23 CEST (Europe/Vienna)

My doctor gave me six months to live,
but when I couldn’t pay the bill
he gave me six months more.    Walter Matthau

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5